211311-95-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide is used as a modulator for AMPA receptors due to its ability to increase glutamate-induced activation of specific AMPA receptor subunits. This makes it a promising candidate for the development of novel therapeutics targeting neurological disorders and conditions related to dopaminergic neuron loss, such as Parkinson's disease.
Used in Neurological Research:
In the field of neuroscience, N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide is utilized as a research tool to study the function and modulation of AMPA receptors. Its selective action on specific AMPA receptor subunits allows researchers to gain insights into the underlying mechanisms of glutamate signaling and its role in cognitive and motor functions.
Used in Drug Development:
N-(2-(4'-cyanobiphenyl-4-yl)propane-2-sulfonaMide's unique properties make it a valuable compound in the development of new drugs targeting AMPA receptors. Its potential to prevent dopaminergic neuron loss in models of Parkinson's disease highlights its therapeutic potential in the treatment of neurodegenerative disorders.

Upstream product

• 256381-13-2 2-(4-bromophenyl)propan-1-amine 
• 623-00-7 4-bromobenzenecarbonitrile 
• 42186-06-1 2-(4-Bromophenyl)propionitrile 
• 16532-79-9 4-Bromophenylacetonitrile 
• 126747-14-6 4-cyanophenylboronic acid 
• 211311-65-8 propane-2-sulfonic acid (2-(4-bromo-phenyl)-propyl)-amide 
• 380608-15-1 N-(2-(4-iodophenyl)propyl)propane-2-sulfonamide 

Relevant academic research and scientific papers

Enantioselective Synthesis of β-Methyl Amines via Iridium-Catalyzed Asymmetric Hydrogenation of N-Sulfonyl Allyl Amines

The iridium-catalyzed asymmetric hydrogenation of several N-sulfonyl allyl amines is reported. All substrates can be easily obtained by the Ir-catalyzed isomerization of N-tosylaziridines reported previously. The commercially available threonine-derived phosphinite (UbaPHOX) iridium complex has been found to be the best catalyst for this catalytic application, affording β-methyl amines with good to excellent ee values (up to 94%). The synthetic potential of this novel methodology was demonstrated by the formal synthesis of Lorcaserin and LY-404187. (Figure presented.).

(BIS)sulfonamide derivatives

The present invention provides (bis) sulfonamide derivatives of formula (I) useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Sulphonamide derivatives

Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formulaR1—L—NHSO2R2??Iin whichR1 represents an unsubstituted or substituted aromatic or heteroaromatic group;R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; andL represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring;and pharmaceutically acceptable salts thereof.Also disclosed are compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.